Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort.
| Autor: | Alahmadi FH; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, and Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, England; Respiratory Therapy Department, College of Medical Rehabilitation Sciences, Taibah University, Medina, Saudi Arabia., Simpson AJ; Division of Sport, Health and Exercise Science, University of Hull, Hull, England., Gomez C; The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden; Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Ericsson M; The Doping Laboratory, The Department of Laboratory Medicine at the Karolinska University Hospital Huddinge, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Thörngren JO; The Doping Laboratory, The Department of Laboratory Medicine at the Karolinska University Hospital Huddinge, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Wheelock CE; Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden; Department of Respiratory Medicine and Allergy, Karolinska University Hospital Solna, Stockholm, Sweden., Shaw DE; Respiratory Research Unit, University of Nottingham, Nottingham, England., Fleming LJ; National Heart and Lung Institute, Imperial College London, London, England., Roberts G; NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, England., Riley J; Respiratory Therapeutic Unit, GlaxoSmithKline, Stockley Park, London, England., Bates S; Respiratory Therapeutic Unit, GlaxoSmithKline, Stockley Park, London, England., Sousa AR; Respiratory Therapeutic Unit, GlaxoSmithKline, Stockley Park, London, England., Knowles R; Knowles Consulting, Stevenage, England., Bansal AT; Acclarogen Ltd, St John's Innovation Centre, Cambridge, England., Corfield J; Areteva R&D, Nottingham, England., Pandis I; Data Science Institute, South Kensington Campus, Imperial College London, London, England., Sun K; Data Science Institute, South Kensington Campus, Imperial College London, London, England., Bakke PS; Department of Clinical Science, University of Bergen, Bergen, Norway., Caruso M; Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy., Chanez P; Assistance Publique-Hôpitaux de Marseille, Clinique des Bronches, de l'Allergie et du Sommeil CIC Nord, Aix-Marseille Université, Marseille, France., Dahlén B; Division of Respiratory Medicine and Allergy, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden., Horvath I; Department of Pulmonology, Semmelweis University, Budapest, Hungary., Krug N; Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany., Montuschi P; Università Cattolica del Sacro Cuore, Milan, Italy., Singer F; Division of Respiratory Medicine, Department of Pediatrics, Inselspital University Hospital Bern, University of Bern, Switzerland., Wagers S; BioSci Consulting, Maasmechelen, Belgium., Adcock IM; National Heart and Lung Institute, Imperial College London, London, England., Djukanovic R; NIHR Southampton Respiratory Biomedical Research Unit, Clinical and Experimental Sciences and Human Development and Health, Southampton, England., Chung KF; National Heart and Lung Institute, Imperial College London, London, England., Sterk PJ; Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Dahlen SE; The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden., Fowler SJ; Division of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, University of Manchester, and Manchester Academic Health Science Centre and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester, England. Electronic address: stephen.fowler@manchester.ac.uk. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Chest [Chest] 2021 Jul; Vol. 160 (1), pp. 53-64. Date of Electronic Publication: 2021 Feb 19. |
| DOI: | 10.1016/j.chest.2021.02.023 |
| Abstrakt: | Background: Although estimates of suboptimal adherence to oral corticosteroids in asthma range from 30% to 50%, no ideal method for measurement exists; the impact of poor adherence in severe asthma is likely to be particularly high. Research Questions: What is the prevalence of suboptimal adherence detected by self-reporting and direct measures? Is suboptimal adherence associated with disease activity? Study Design and Methods: Data were included from individuals with severe asthma taking part in the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes) study and prescribed daily oral corticosteroids. Participants completed the Medication Adherence Report Scale, a five-item questionnaire used to grade adherence on a scale from 1 to 5, and provided a urine sample for analysis of prednisolone and metabolites by liquid chromatography-mass spectrometry. Results: Data from 166 participants were included in this study: mean (SD) age, 54.2 (± 11.9) years; FEV Interpretation: Low adherence is a common problem in severe asthma, whether measured directly or self-reported. We report poor agreement between the two methods, suggesting some disassociation between self-assessment of medication adherence and regular oral corticosteroid use, which suggests that each approach may provide complementary information in clinical practice. (Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|